CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 161 enrolled
Drug / intervention
Pitavastatin +1 moredrug
Likely dose
Pitavastatin 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00889226
NCT00889226Phase 4Completed
CompareCT.gov

A Randomized, Open Label, Dose Titration Study to Evaluate the Efficacy and Safety of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia

JW Pharmaceutical·interventional·Posted Apr 28, 2009·Updated Sep 17, 2019

In Brief

A Phase 4 clinical trial evaluating Pitavastatin and Atorvastatin for Hypercholesterolemia With Type2DM. Completed, enrolled 161 participants.

Detailed Summary

A randomized, open label, dose titration study to evaluate the efficacy and safety of Pitavastatin compared to atorvastatin in Type 2 Diabetes Mellitus with hypercholesterolemia

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia With Type2DM
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 28, 2009
Enrollment StartApr 1, 2008
Primary CompletionMay 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.2 years ago

Interventions

Pitavastatindrug

Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks

Atorvastatindrug

Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks